Visual outcomes using the light adjustable lens in patients with previous LASIK and/or PRK (laser eye surgery)

ISRCTN ISRCTN57719133
DOI https://doi.org/10.1186/ISRCTN57719133
Secondary identifying numbers 7459325
Submission date
21/02/2023
Registration date
21/02/2023
Last edited
20/11/2023
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Eye Diseases
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English Summary

Background and study aims
The Light Adjustable Lens (LAL) from RxSight, Inc. (Aliso Viejo, CA) is an intraocular lens (IOL) used in cataract surgery that enables vision customization after implantation and ocular healing has occurred.
A second-generation IOL from RxSight (LAL 2.0) incorporates an enhanced UV absorber (ActivShield) that may increase the stability of the IOL and refractive outcomes.
Patients with a history of previous refractive surgery pose problems with postoperative refractive error following cataract surgery. This population of patients is particularly well-suited for LAL technology.
Previous studies have reported good outcomes of the LAL in post refractive patients, but a large-sample clinical study has yet to be published on post LASIK or PRK patients electing for the second-generation ActivShield LAL (LAL 2.0) in the peer reviewed literature. The aim of this study is to report on the safety and visual acuity (VA) outcomes using the second generation, ActivShield LAL (LAL 2.0) in patients with previous history of LASIK or PRK. To our knowledge, this retrospective study will be the first report of visual outcomes using the ActiShieldTM (LAL 2.0) in post LASIK or PRK patients in the peer-reviewed literature.

Who can participate?
Patients with previous history of LASIK and/or PRK undergoing cataract surgery with use of the ActivShield LAL (LAL 2.0) and adequate pupil dilation of 6.5 mm or more.

What does the study involve?
Having cataract surgery and using the ActivShield LAL as the IOL implant at the time of the cataract surgery. It will involve up to 5 follow-up light treatments to adjust the power of the LAL after surgery to further improve the patient's vision.

What are the possible benefits and risks of participating?
The benefits would include improved vision from correction of the cataract and improved vision from correction of refractive error (glasses) through adjustment of the power of the LAL after surgery. All surgery and testing is “standard of care” with no “study specific” surgery or tests performed. Risks are related to those of cataract surgery including vision loss and the need for additional surgery.

Where is the study run from?
It is run from the surgery centers where cataract surgeries are performed and Praxis Vision where the post-op light treatments are performed (USA)

When is the study starting and how long is it expected to run for?
This retrospective chart review will look at patients from approximately July, 2021, through December, 2022.

Who is funding the study?
Investigator initiated and funded

Who is the main contact?
David V. Folden, MD, dfolden@nseyespecialists.com

Contact information

Dr David Folden
Principal Investigator

10452 Vermillion Cir NE
Blaine
55449
United States of America

ORCiD logoORCID ID 0000-0002-9912-7719
Phone +1 6129643234
Email dfolden@nseyespecialists.com

Study information

Study designObservational retrospective chart review
Primary study designObservational
Secondary study designCase series
Study setting(s)Medical and other records
Study typeOther
Participant information sheet Not applicable (retrospective study)
Scientific titleVisual outcomes using an enhanced UV protected light adjustable lens in patients with previous LASIK and/or PRK
Study acronymVOwLAL for PO-LASIK & PRK
Study hypothesisThe second-generation, ActivShield LAL (LAL 2.0), used in patients undergoing cataract surgery and with previous history of LASIK or PRK should provide excellent refractive outcomes.
Ethics approval(s)Approved 15/02/2023, SALUS IRB (2111 W. Braker Lane, Ste 300, Austin, TX 78758, USA; +1 888-834-6632; clientservices@salusirb.com), ref: 2023.02.15 Exempt Determination
ConditionUse of the Light Adjustable Lens in Post-LASIK and PRK patients
InterventionThis retrospective observational case series assessed the VA and safety outcomes of a consecutive series of post LASIK or PRK patients after cataract extraction and IOL implantation with the ActivShieldTM LAL 2.0 in a private practice setting between July 2021 and December 2022.
The primary outcome measures for this study were monocular uncorrected distance visual acuity (UDVA), monocular mean spherical equivalent (SE), and monocular mean residual cylinder for emmetropic-goal eyes at the 3+ month post surgical follow-up. Safety outcomes reported include serious adverse events (AEs) occurring at the time of surgery extending out to the final postoperative examination.
All final postoperative exams included slit lamp biomicroscopy, intraocular pressure, MRx with corrected distance visual acuity (CDVA), and uncorrected distance visual acuity (UDVA). Distance VA testing was achieved using a computer calibrated Snellen chart under photopic conditions. A standard phoropter was used to determine the subjective MRx rounded to steps of 0.25 D. All testing was “standard of care” and there were no “study specific” tests performed.
Intervention typeProcedure/Surgery
Primary outcome measureMeasured using patient records:
1. Monocular uncorrected distance visual acuity (UDVA)
2. Monocular mean spherical equivalent (SE)
3. Monocular mean residual cylinder for emmetropic-goal eyes at the 3+ month post surgical follow-up.
4. Safety outcomes reported include serious adverse events (AEs) occurring at the time of surgery extending out to the final postoperative examination.
Secondary outcome measuresThere are no secondary outcome measures
Overall study start date01/07/2021
Overall study end date31/12/2022

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit40 Years
Upper age limit90 Years
SexBoth
Target number of participantsApproximately 40 patients and 50 eyes.
Total final enrolment40
Participant inclusion criteria1. Patients who receive the ActivShield LAL with their cataract surgery
2. Have previous history of LASIK and/or PRK
3. Have pupil dilation of 6.5 mm or greater
4. Age between 40-90 years
Participant exclusion criteriaPatients with retinal or macular disease, clinically significant corneal abnormalities, corneal scarring, or ectasia were excluded from the study.
Recruitment start date01/07/2021
Recruitment end date31/12/2022

Locations

Countries of recruitment

  • United States of America

Study participating centres

North Metro Surgery Center
11855 Ulysses Street, Suite 270
Blaine
55434
United States of America
Praxis Vision
3601 76th Street W, Suite #150
Edina
55435
United States of America
Edina Specialty Surgery Center
4100 Minnesota Drive, #200
Edina
55435
United States of America

Sponsor information

North Suburban Eye Specialists
Hospital/treatment centre

3777 Coon Rapids Blvd NW, Suite 100
Coon Rapids
55433
United States of America

Phone +1 7630-421-7420
Email dfolden@nseyespecialists.com
Website https://nseyespecialists.com/

Funders

Funder type

Other

Investigator initiated and funded

No information available

Results and Publications

Intention to publish date31/08/2023
Individual participant data (IPD) Intention to shareYes
IPD sharing plan summaryStored in non-publicly available repository, Not expected to be made available
Publication and dissemination planPlanned publication in a high-impact peer-reviewed journal.
IPD sharing planExisting medical records are kept at the Twin Cities Eye Consultants’ clinic locations and LDD treatment records at Praxis Vision. Patients will be de-identified in the analysis and be assigned a Subject ID number.
Electronic charts are stored in a computer which is password protected. The database used for analysis will also be password protected. The Principal Investigator and the LDD Specialist will perform the analysis.
The data used for analysis will be stored according to Clinic guidelines which is generally seven years. The outcomes analysis database would be stored for 7 years, and deleted electronically.
Consents from participants will not be obtained because of the retrospective design of the study and all PHI will be de-identified. It has already received "Exempt" status approval from Salus IRB.
Data will be available through attempted publication.
Any raw data generated during the current study are not expected to be made available unless requested by the publication source after the manuscript is submitted.

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article 06/11/2023 20/11/2023 Yes No

Editorial Notes

20/11/2023: Publication reference added.
21/02/2023: Trial's existence confirmed by Salus IRB.